AI-generated summary
The authors ran a small randomized feasibility study of low level laser therapy (photobiomodulation) added to usual care for breast cancer-related lymphedema, with 17 participants randomized to laser or control. They report that recruitment, randomization, adherence and retention were acceptable and that no serious adverse reactions occurred. Clinical outcomes did not show additional benefit from the laser, and the study was not designed to test effectiveness.
- Participants
- 17
- Who or what was studied
- Patients with breast cancer-related lymphedema recruited from the Southern District Health Board in New Zealand
- Wavelengths
- 980, 810 nm
- Limits stated in the abstract
- The study was a small feasibility trial with 17 participants, so it cannot establish effectiveness, and clinical outcomes showed no additional benefit from the laser.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm
- Energy density (fluence)
- 6J/cm2
- Power density (irradiance)
- 100 mW/cm2
- Power
- 500 mW
- Total energy
- 30J, 300 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Laser, Low-level laser therapy, Randomized controlled trial, Control group, Irradiance, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.